Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Conduit Pharmaceuticals Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered and Carry Forward Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||||||||||||
| Equity | Common Stock, par value $0.0001 per share | Other(1) | 69,240 | (2) | $ | 1.97005 | (1) | $ | 136,406.26 | 0.00015310 | $ | 21 | ||||||||||||
| Total Offering Amounts | $ | 136,406.26 | $ | 21 | ||||||||||||||||||||
| Total Fee Offsets | $ | 0 | ||||||||||||||||||||||
| Net Fee Due | $ | 21 | ||||||||||||||||||||||
| (1) | Calculated solely for purposes of this offering under Rules 457(c) and 457(h) of the Securities Act of 1933, as amended (the “Securities Act”), on the basis of the average of the high and low prices per share of Registrant’s common stock on February 4, 2025 as reported by The Nasdaq Stock Market. | |
| (2) | Represents shares, not previously registered, of the Registrant’s common stock that may be issued under the Conduit Pharmaceuticals Inc. 2023 Stock Incentive Plan (the “2023 Plan”) pursuant to an annual “evergreen” increase provision contained in the 2023 Plan. Pursuant to Rule 416(a) promulgated under the Securities Act, this registration statement shall also cover any additional shares of Registrant’s common stock that become issuable under the 2023 Plan by reason of any stock dividend, stock split, recapitalization, or other similar transaction effected without receipt of consideration that increases the number of outstanding shares of Registrant’s common stock, as applicable. |
